302 related articles for article (PubMed ID: 35077703)
1. Developing Therapy for Transthyretin Amyloidosis.
Campbell CM; Zhang K; Lenihan DJ; Witteles R
Am J Med; 2022 Apr; 135 Suppl 1():S44-S48. PubMed ID: 35077703
[TBL] [Abstract][Full Text] [Related]
2. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
[TBL] [Abstract][Full Text] [Related]
3. A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
Benbrahim M; Norman K; Sanchorawala V; Siddiqi OK; Hughes D
J Cardiovasc Pharmacol; 2021 May; 77(5):544-548. PubMed ID: 33657048
[TBL] [Abstract][Full Text] [Related]
4. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
5. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J
Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442
[TBL] [Abstract][Full Text] [Related]
6. RNA-targeting and gene editing therapies for transthyretin amyloidosis.
Aimo A; Castiglione V; Rapezzi C; Franzini M; Panichella G; Vergaro G; Gillmore J; Fontana M; Passino C; Emdin M
Nat Rev Cardiol; 2022 Oct; 19(10):655-667. PubMed ID: 35322226
[TBL] [Abstract][Full Text] [Related]
7. Advances in the treatment of hereditary transthyretin amyloidosis: A review.
Gertz MA; Mauermann ML; Grogan M; Coelho T
Brain Behav; 2019 Sep; 9(9):e01371. PubMed ID: 31368669
[TBL] [Abstract][Full Text] [Related]
8. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
9. Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones.
Capovilla TM; Lalario A; Rossi M; Porcari A; Aimo A; Limongelli G; Emdin M; Merlo M; Sinagra G
Heart Fail Clin; 2024 Jul; 20(3):333-341. PubMed ID: 38844304
[TBL] [Abstract][Full Text] [Related]
10. [Neurological manifestations of ATTR amyloidosis].
Pernice HF; Hahn K
Inn Med (Heidelb); 2023 Sep; 64(9):848-854. PubMed ID: 37555967
[TBL] [Abstract][Full Text] [Related]
11. Therapy of ATTR Cardiac Amyloidosis: Current Indications.
Di Lisi D; Di Stefano V; Brighina F; Galassi AR; Novo G
Curr Probl Cardiol; 2023 Feb; 48(2):101487. PubMed ID: 36336119
[TBL] [Abstract][Full Text] [Related]
12. Specific Therapy in Transthyretin Amyloid Cardiomyopathy: Future Perspectives Beyond Tafamidis.
Saro R; Allegro V; Merlo M; Dore F; Sinagra G; Porcari A
Heart Fail Clin; 2024 Jul; 20(3):343-352. PubMed ID: 38844305
[TBL] [Abstract][Full Text] [Related]
13. Overview of Current and Emerging Therapies for Amyloid Transthyretin Cardiomyopathy.
Maurer MS
Am J Cardiol; 2022 Dec; 185 Suppl 1():S23-S34. PubMed ID: 36371281
[TBL] [Abstract][Full Text] [Related]
14. Targeted Therapeutics for Transthyretin Amyloid Cardiomyopathy.
Campbell CM; Baiyee CAMT; Almaani S; Bumma N; Sharma N; LoRusso S; Redder E; Bittengle J; Pfund K; Friemer M; Tong M; Kahwash R; Efebera Y; Parikh S; Vallakati A
Am J Ther; 2023 Sep-Oct 01; 30(5):e447-e453. PubMed ID: 37713689
[TBL] [Abstract][Full Text] [Related]
15. Transthyretin Cardiac Amyloidosis and Novel Therapies to Treat This Not-so-rare Cause of Cardiomyopathy.
Capustin M; Frishman WH
Cardiol Rev; 2021 Sep-Oct 01; 29(5):263-273. PubMed ID: 34397539
[TBL] [Abstract][Full Text] [Related]
16. [Specific pharmacological treatment guide for transthyretin amyloid cardiomyopathy, 2021].
Villanueva E; Carretero M; Aguirre MA; Negro A; Belziti CA; Posadas-Martínez ML; Nucifora EM; Baratta S; Costabel JP; Higa C; Rivas C; Fernández A; Quiroga A; Dumont CA; Volberg VI; Streitenberg GM; Perez de Arenaza D
Medicina (B Aires); 2022; 82(2):275-288. PubMed ID: 35417392
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy review: Emerging treatment modalities in transthyretin cardiac amyloidosis.
Plumadore E; Lombardo L; Cabral KP
Am J Health Syst Pharm; 2022 Jan; 79(2):52-62. PubMed ID: 34491302
[TBL] [Abstract][Full Text] [Related]
18. Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy.
Nuvolone M; Girelli M; Merlini G
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555787
[TBL] [Abstract][Full Text] [Related]
19. Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies.
Rozenbaum MH; Garcia A; Grima D; Tran D; Bhambri R; Stewart M; Li B; Heeg B; Postma M; Masri A
Eur Heart J Qual Care Clin Outcomes; 2022 Aug; 8(5):529-538. PubMed ID: 33895806
[TBL] [Abstract][Full Text] [Related]
20. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy?
Müller ML; Butler J; Heidecker B
Eur J Heart Fail; 2020 Jan; 22(1):39-53. PubMed ID: 31912620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]